Harvard Breast Cancer: New Horizons, Current Controversies 2025

Session I: Radiation Oncology

1. 50 Years of Radiation Therapy – Abram Recht

2. Standard Radiation Therapy: The Long and the Short – Julia Wong

3. The Future of Breast Radiation Therapy – Atif Khan

4. Radiopharmaceuticals – Heather Jacene

5. Q&A – Abram Recht, Atif Khan, Julia Wong, Heather Jacene

Session II: Pathology

6. Lobular Breast Cancer – Stuart Schnitt

7. ctDNA: The Evolving Role for Molecular Diagnostics – Stefania Morganti

8. Q&A – Stuart Schnitt, Stefania Morganti

Special Lecture

9. What’s New in Supportive Care: Management of Gastrointestinal Side Effects – Sydney Smith & Julie Bosworth

10. Essentials of Germline Genetics – Judy Garber

11. Q&A – Julie Bosworth, Sydney Smith, Judy Garber

12. Schwartz Rounds: A Complex Case – Ann Partridge

13. Tumor Board: Early Breast Cancer – Harold Burstein, Faina Nakhlis, Julia Wong, Brittany Bychkovsky, Adrienne Waks, Filipa Lynce, Elizabeth Mittendorf

Session III: HER2 Positive Breast Cancer

14. New Approaches in Early Stage HER2 Positive Breast Cancer – Adrienne Waks

15. The Progress Continues: Late Stage HER2 Positive Breast Cancer – Sarah Sammons

16. Can We Cure Metastatic Breast Cancer? – Nancy Lin

17. Q&A – Sara Tolaney, Sarah Sammons, Nancy Lin, Adrienne Waks

Special Lecture

18. Racial Differences in Breast Cancer Survival – Erica Warner

19. Inflammatory Breast Cancer – Filipa Lynce

20. Early Drug Discovery in Breast Cancer – Antonio Giordano

21. Lifestyle/Diet/Exercise in Breast Cancer Patients – Jennifer Ligibel

Session IV: Surgery

1. Oncoplastic Reconstruction: Common Indications and Outcomes – Indranil Sinha

2. The Axilla After Neoadjuvant Therapy: How Much Is Too Much? – Elizabeth Mittendorf

3. Implications of the SOUND Trial – Olga Kantor

4. Cryoblation Instead of Surgery – Francys Verdial

5. Q&A – Barbara Smith, Indranil Sinha, Olga Kantor, Francys Verdial, Elizabeth Mittendorf

6. Schlager Lecture: Immunotherapy in Early Breast Cancer: Today and Tomorrow – Marleen Kok

Session V: Triple Negative Breast Cancer (TNBC)

7. Small TNBCs: How Small Is Small Enough? – Steven Isakoff

8. Antibody Drug Conjugates in TNBC & Refractory ER Positive Breast Cancer – Ana Garrido-Castro

9. Immunotherapy in TNBC – Guilherme Nader Marta

10. Managing Endocrine Side Effects of Immunotherapy – Elad Sharon

11. Q&A – Steven Isakoff, Ana Garrido-Castro, Guilherme Nader Marta, Elad Sharon

12. Tumor Board: Advanced Breast Cancer – Rachel Freedman, Barbara Smith, Sarah Sammons, Erica Mayer, Laura Spring, Leticia Varella, Guilherme Nader Marta, Daniel Abravanel

Session VI: ER Positive Breast Cancer

13. New Approaches in Early ER Positive Breast Cancer – Erica Mayer

14. PI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target – Dejan Juric

15. Advanced ER Positive Breast Cancer: A Surfeit of Choices – Seth Wander

16. Emerging Antibody Drug Conjugates in ER Positive Breast Cancer – Paolo Tarantino

17. Q&A – Erica Mayer, Seth Wander, Paolo Tarantino, Dejan Juric

18. CDK4/6: Which One? For Whom? – Debate (Shana Berwick & Laura Spring)

19. ASCO Highlights – Harold Burstein

20. Closing Remarks – Harold Burstein